[Research progress of lymphocyte activation gene 3 (LAG-3) in tumor immunotherapy and parasite disease]
Related Experiment Video
Updated: Sep 5, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Dewei Li1, Chuanshan Zhang2, Jing Li3
1Department of Physiology, College of Basic Medicine, Xinjiang Medical University, Urumqi 830054, China.
Lymphocyte activation gene 3 (LAG-3) is a novel immune checkpoint molecule, which is mainly expressed in activated T cell and regulatory T cells (Tregs). Induced by T cell receptors (TCR) and cytokines, LAG-3 is activated by binding to ligands such as MHC II and fibrinogen like protein 1, which then upregulates function of Tregs, negatively regulates TCR signal transduction and affects cytokine secretion. All these regulations lead to dropped body immunity and the immune escape of pathogens. In recent years, LAG-3 has become a new potential target for tumor immunotherapy due to its multiple ligands, wide expression and significant efficacy. Hereby, we reviewed and summarized the structure, ligand and function of LAG-3, as well as its application in tumor immunotherapy and parasitic infection.
Lymphocyte activation gene 3 (LAG-3) is a novel immune checkpoint molecule, which is mainly expressed in activated T cell and regulatory T cells (Tregs). Induced by T cell receptors (TCR) and cytokines, LAG-3 is activated by binding to ligands such as MHC II and fibrinogen like protein 1, which then upregulates function of Tregs, negatively regulates TCR signal transduction and affects cytokine secretion. All these regulations lead to dropped body immunity and the immune escape of pathogens. In recent years, LAG-3 has become a new potential target for tumor immunotherapy due to its multiple ligands, wide expression and significant efficacy. Hereby, we reviewed and summarized the structure, ligand and function of LAG-3, as well as its application in tumor immunotherapy and parasitic infection.
More Related Videos
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
07:17Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice
Published on: June 22, 2016
Related Concept Videos
Tumor Immunotherapy
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...